High level of MUC1 in serum of ovarian and breast cancer patients inhibits huHMFG-1 dependent cell-mediated cytotoxicity (ADCC)

María Moreno, Hetty J. Bontkes, Rik J. Scheper, Peter Kenemans, René H.M. Verheijen, Silvia von Mensdorff-Pouilly

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

The huHMFG-1 (AS1402) antibody is a humanised IgG1 directed against MUC1 and is currently in clinical trials for the treatment of breast carcinoma. Adenocarcinomas over-express and shed MUC1, and high MUC1 serum levels are associated with progressive disease. Here, we have investigated the effects of MUC1 present in sera from breast and ovarian cancer patients and that of NK cells on in vitro huHMFG-1-mediated ADCC, performed with and without the addition of various cytokines. Screening for patients with high levels of NK cells bearing the FcγRIIIa-158V polymorphism, adjusting the dosage to circulating levels of MUC1 and co-administration of NK cell activating cytokines may increase the efficacy of huHMFG-1 treatment.

Original languageEnglish
Pages (from-to)47-55
Number of pages9
JournalCancer Letters
Volume257
Issue number1
DOIs
Publication statusPublished - 8 Nov 2007

Cite this

@article{89fa93d175134fbbbdb9f62939ee1b4a,
title = "High level of MUC1 in serum of ovarian and breast cancer patients inhibits huHMFG-1 dependent cell-mediated cytotoxicity (ADCC)",
abstract = "The huHMFG-1 (AS1402) antibody is a humanised IgG1 directed against MUC1 and is currently in clinical trials for the treatment of breast carcinoma. Adenocarcinomas over-express and shed MUC1, and high MUC1 serum levels are associated with progressive disease. Here, we have investigated the effects of MUC1 present in sera from breast and ovarian cancer patients and that of NK cells on in vitro huHMFG-1-mediated ADCC, performed with and without the addition of various cytokines. Screening for patients with high levels of NK cells bearing the FcγRIIIa-158V polymorphism, adjusting the dosage to circulating levels of MUC1 and co-administration of NK cell activating cytokines may increase the efficacy of huHMFG-1 treatment.",
keywords = "ADCC, huHMFG-1 monoclonal antibody, MUC1, NK cells",
author = "Mar{\'i}a Moreno and Bontkes, {Hetty J.} and Scheper, {Rik J.} and Peter Kenemans and Verheijen, {Ren{\'e} H.M.} and {von Mensdorff-Pouilly}, Silvia",
year = "2007",
month = "11",
day = "8",
doi = "10.1016/j.canlet.2007.06.016",
language = "English",
volume = "257",
pages = "47--55",
journal = "Cancer Letters",
issn = "0304-3835",
publisher = "Elsevier Ireland Ltd",
number = "1",

}

High level of MUC1 in serum of ovarian and breast cancer patients inhibits huHMFG-1 dependent cell-mediated cytotoxicity (ADCC). / Moreno, María; Bontkes, Hetty J.; Scheper, Rik J.; Kenemans, Peter; Verheijen, René H.M.; von Mensdorff-Pouilly, Silvia.

In: Cancer Letters, Vol. 257, No. 1, 08.11.2007, p. 47-55.

Research output: Contribution to journalArticleAcademicpeer-review

TY - JOUR

T1 - High level of MUC1 in serum of ovarian and breast cancer patients inhibits huHMFG-1 dependent cell-mediated cytotoxicity (ADCC)

AU - Moreno, María

AU - Bontkes, Hetty J.

AU - Scheper, Rik J.

AU - Kenemans, Peter

AU - Verheijen, René H.M.

AU - von Mensdorff-Pouilly, Silvia

PY - 2007/11/8

Y1 - 2007/11/8

N2 - The huHMFG-1 (AS1402) antibody is a humanised IgG1 directed against MUC1 and is currently in clinical trials for the treatment of breast carcinoma. Adenocarcinomas over-express and shed MUC1, and high MUC1 serum levels are associated with progressive disease. Here, we have investigated the effects of MUC1 present in sera from breast and ovarian cancer patients and that of NK cells on in vitro huHMFG-1-mediated ADCC, performed with and without the addition of various cytokines. Screening for patients with high levels of NK cells bearing the FcγRIIIa-158V polymorphism, adjusting the dosage to circulating levels of MUC1 and co-administration of NK cell activating cytokines may increase the efficacy of huHMFG-1 treatment.

AB - The huHMFG-1 (AS1402) antibody is a humanised IgG1 directed against MUC1 and is currently in clinical trials for the treatment of breast carcinoma. Adenocarcinomas over-express and shed MUC1, and high MUC1 serum levels are associated with progressive disease. Here, we have investigated the effects of MUC1 present in sera from breast and ovarian cancer patients and that of NK cells on in vitro huHMFG-1-mediated ADCC, performed with and without the addition of various cytokines. Screening for patients with high levels of NK cells bearing the FcγRIIIa-158V polymorphism, adjusting the dosage to circulating levels of MUC1 and co-administration of NK cell activating cytokines may increase the efficacy of huHMFG-1 treatment.

KW - ADCC

KW - huHMFG-1 monoclonal antibody

KW - MUC1

KW - NK cells

UR - http://www.scopus.com/inward/record.url?scp=34648820280&partnerID=8YFLogxK

U2 - 10.1016/j.canlet.2007.06.016

DO - 10.1016/j.canlet.2007.06.016

M3 - Article

VL - 257

SP - 47

EP - 55

JO - Cancer Letters

JF - Cancer Letters

SN - 0304-3835

IS - 1

ER -